The Competitiveness of Public Medicine Procurement in Chile

Executive Summary

Chile’s public pharmaceutical market is anchored by one buyer — CENABAST, the central procurement agency, which accounts for roughly four of every five pesos of public medicine purchasing. That concentration makes a single question decisive for anyone selling into, or studying, this market: how much competition is there in that opportunity?

We measured it from the public record — registrations (ISP), customs imports, and the full tender and purchase-order trail of Mercado Público. Five findings stand out.

1. CENABAST dominates, so its competitive posture sets the market’s. It is ~82% of public-pharma purchasing value (2024–2025). How it buys is how the market behaves.
2. A large share of its buying never reaches a competitive tender. Roughly 2 of every 5 pesos (40–48%, both years) of CENABAST’s medicine spend has no public tender on record behind it.
3. Even inside the tenders, competition is thin. About 1 in 5 awarded pharma lines drew a single bidder — and those lines alone account for 37% of awarded value. Two-thirds of value was awarded with two bidders or fewer.
4. Thin competition has a measurable price. Within the same molecule, single-bidder tenders are awarded at ~23% higher unit prices (median) than tenders with three or more bidders — a gap that holds in three of every four molecules. Competition is not just a structural nicety; its absence is paid for in money.
5. But most direct buying is legitimate — the contestable slice is a minority. Applying the legal grounds for direct purchase to 2025 spend, roughly 7 of every 10 pesos could not have been competed even in principle (vaccines bought through the PAHO regional fund, sole-source patented medicines, or molecules whose tender had already gone deserted). Only about 1 in 10 went to medicines several suppliers can make, with no failed tender to explain the direct award. That is the contestable opening — and it is smaller, and more specific, than headline figures suggest.

The next pages expand each finding with data and sources, and close with what it means for a new entrant and for the system. Where the genuine opportunities sit — which molecules, which therapeutic areas — is the question our platform answers; this report quantifies the problem, not the shortlist.

1. How Chile buys its medicines

Public pharmaceutical procurement in Chile runs through Mercado Público, the national e-procurement platform, under Law 19.886 (the public-contracts law, substantially modernised by Law 21.634 in 2024). Most public medicine volume is intermediated by CENABAST (Central de Abastecimiento del Sistema Nacional de Servicios de Salud), the central buying agency, which negotiates framework deals and supplies hospitals, primary care, and — under Law 21.198 — private pharmacies and non-profit establishments.

CENABAST’s weight is decisive. Measured on executed purchase orders, it represents 82.4% of public-pharma purchasing value in 2024 and 81.4% in 2025. It is not the only public buyer — hundreds of hospitals and municipalities buy directly — but it is, by a wide margin, the one that sets prices and availability for the system.

Procurement moves through two channels. The competitive tender (licitación) is the default: an open call, multiple bidders, an award. The direct purchase (trato directo) is the legal exception, permitted only on specific grounds (Article 71 of the 2024 Regulation): a single available supplier, a prior tender that drew no bidders, an emergency, a small amount, and a few others. The 2024 reform tightened these grounds and now requires the buyer to publish the decision in advance.

This report asks a simple question of that structure: of everything CENABAST buys, how much is genuinely subject to competition — and what does the lack of it cost?

2. How much is actually competed

The first answer is: less than the tender-centric view suggests.

Two of every five pesos never reach a tender. Of CENABAST’s pharma purchasing, the share with no public tender on record behind it is 47.7% in 2024 and 40.7% in 2025 — steady across both years. This is the purchasing that runs as direct award or framework execution rather than open competition.

And where there is a tender, competition is thin. Across awarded pharma lines:

• 19% drew a single valid bidder — yet those single-bidder lines account for 37% of awarded value.
• Lines with two bidders or fewer make up 67% of awarded value.
• Genuine multi-bidder contests (5+) are common by count but small by value.

The picture is not an absence of tenders; it is an abundance of tenders with very few participants. That distinction matters, because the number of bidders turns out to be the single most important determinant of the price the State pays — as the next section shows.

3. The cost of thin competition

It is intuitive that more competition lowers prices. What’s worth doing is putting a number on it.

We compared, within the same molecule (same active ingredient, dose and form), the awarded unit price when a tender drew a single bidder versus when it drew three or more. Holding the molecule fixed removes the obvious confounder that expensive specialty drugs naturally attract fewer bidders.

The result is consistent and large:

• Across 1,454 molecules with awards in both situations, single-bidder tenders were awarded at a median ~23% higher unit price than the same molecule’s competitive tenders.
• The premium appears in three of every four molecules.
• It scales with competition: moving from one bidder to two narrows the gap to ~8%; one to three-or-more widens it to ~23%.

In other words, thin competition is not a cosmetic feature of the market — it carries a recurring, measurable cost, paid by the public system on the molecules where only one supplier shows up. For a prospective entrant, the same fact reads in reverse: finding the opportunities where few competitors are likely is central to the strategy — those are precisely the molecules where a credible second bidder both captures business and resets the price.

(One clarification: this comparison is always within the same molecule. Comparing across different molecules makes the gap look far larger, but that mixes cheap and expensive products and overstates the effect.)

4. Is the direct buying justified?

A large non-competitive share is not, by itself, evidence of a problem. Much of what the State buys directly cannot be competed — and the law recognises this. The useful question is how much of CENABAST’s direct buying fits the legal grounds, and how much does not.

We classified CENABAST’s 2025 direct (no-tender) medicine spend against the verifiable grounds for direct purchase:

Read plainly: about seven of every ten pesos could not have been competed even in principle — vaccines bought through the PAHO Revolving Fund (a pooled regional mechanism with a single price, by design not a national tender), patented sole-source medicines, or molecules whose tender that year had drawn no valid bid. The unclassified remainder is, on inspection, overwhelmingly patented specialty biologics — which belong with the justified majority.

That leaves a contestable slice of roughly 1 in 10 pesos — medicines that more than one supplier is registered to make, bought directly with no failed tender to explain it. The figure is stable across 2024 (9.4%) and 2025 (9.0%). It is not an accusation: there can be legitimate reasons — urgency, supply continuity — that the public record does not show. But it is the part of the market where competition was, in principle, possible and did not happen.

This is the honest middle ground that headline numbers miss. The non-competitive share is large, but most of it is structurally unavoidable. The real, addressable opening is the ~10% that is contestable — and identifying which molecules and therapeutic areas sit inside it is a different, harder question than measuring its size.

5. Conclusion & implications

Chile’s public-pharma market is dominated by one buyer, a large share of whose purchasing is not competitively contested — and where competition is thin, the State pays a measurable premium (~23% within the same molecule). Yet most of the non-competitive buying is legitimate: vaccines, sole-source biologics, and failed tenders together explain roughly 70% of direct spend. The genuinely contestable opening is a stable ~10% — smaller than it first appears, but real.

For a new entrant, the implication is precise. The opportunity is not "CENABAST is big" (true but unactionable), nor "the market isn’t competitive" (true but incomplete). It is the specific, contestable slice: molecules with a single incumbent bidder, no patent barrier, and no failed tender — exactly where a credible second supplier both wins business and resets the price.

For the system, the implication is that "more tenders" is not the same as "more competition." A tender with one bidder costs nearly as much as a direct award. The lever is participation, not procedure.

Which molecules are contestable, what they are worth, and who actually supplies each layer of the market — competitive tenders, direct buys, imports, and the private channel — is what our platform maps, molecule by molecule. This report sizes the problem; the shortlist is the product.

6. Methodology note

Sources (all public): ISP sanitary registrations; National Customs import records; Mercado Público / ChileCompra tender and purchase-order open data; CENABAST’s official annual accounts; PAHO Revolving Fund documentation. Window: purchase orders 2024–2025; tender history 2020–2026. Unit of analysis: pharmaceutical line-items (UNSPSC 51), matched to a canonical molecule key (active ingredient + dose + form).

Definitions. No tender on record = a purchase order with no linked public tender. Single-bidder = one valid bid after excluding disqualified and placeholder bids. Contestable = a directly-purchased molecule with two or more registered suppliers and no same-year deserted tender, excluding vaccines and small amounts.

Limitations (stated plainly). Import volumes are sell-in, not consumption. The private-retail channel is not yet in our historical data — we are capturing it from 2026 onward. Supplier identity across data sources is canonicalised but imperfect. "Contestable" measures possibility of competition, not legality: some directly-purchased molecules may have valid justifications (urgency, continuity) not visible in the public record. We do not publish supplier or molecule names.

What this report does not contain. The molecule-level opportunity map and cross-channel supplier intelligence are part of our platform, not this document.

7. About Lanin Pharma

Lanin Pharma is a market-intelligence platform for Chile’s public pharmaceutical market — and, from there, the rest of Latin America. We map who actually buys each molecule, through which channel, and at what price, across the registration, import, tender, and purchase layers of the market.

This report’s methodology was reviewed by Aleffarma Regulatory Affairs.

If you work in this market and want one concrete data point: tell us a molecule and we’ll tell you which category of this analysis it falls into (vaccine/PAHO, sole-source, deserted tender, or contestable). Write to us through the page.

This report is provided for informational purposes. It does not constitute investment, registration, or legal advice.

Next edition: a quarterly State of Chilean Generic Tenders. © 2026 Lanin Pharma — a product of Lanin Intelligence.